Non-neutralizing antibodies targeting the immunogenic regions of HIV-1 envelope reduce mucosal infection and virus burden in humanized mice.

Antibodies are principal immune components elicited by vaccines to induce protection from microbial pathogens. In the Thai RV144 HIV-1 vaccine trial, vaccine efficacy was 31% and the sole primary correlate of reduced risk was shown to be vigorous antibody response targeting the V1V2 region of HIV-1...

Full description

Bibliographic Details

Published in:	PLoS Pathogens
Main Authors:	Catarina E Hioe, Guangming Li, Xiaomei Liu, Ourania Tsahouridis, Xiuting He, Masaya Funaki, Jéromine Klingler, Alex F Tang, Roya Feyznezhad, Daniel W Heindel, Xiao-Hong Wang, David A Spencer, Guangnan Hu, Namita Satija, Jérémie Prévost, Andrés Finzi, Ann J Hessell, Shixia Wang, Shan Lu, Benjamin K Chen, Susan Zolla-Pazner, Chitra Upadhyay, Raymond Alvarez, Lishan Su
Format:	Article
Language:	English
Published:	Public Library of Science (PLoS) 2022-01-01
Online Access:	https://journals.plos.org/plospathogens/article/file?id=10.1371/journal.ppat.1010183&type=printable